Ivan Dikic

Ivan Dikic is Professor of Biochemistry and Director of the Institute for Biochemistry 2 at Goethe University and a Fellow of the Max Planck Institute for Biophysics in Frankfurt. He is an international leader in the fields of ubiquitin biology and autophagy and explores pathological alterations in these pathways related to human disease development, including cancer, infectious diseases, and neurodegeneration.

His recent interests focus on proximity-inducing drugs including PROTACs and molecular glues, where he leads a large cluster consortium, PROXIDRUGS. He was a co-founder of two biotech companies: Caraway Therapeutics in Boston (acquired by Merck in 2023) and Vivlion Biotech GmbH in Germany.

Ivan Dikic is an elected member of the EMBO, the German National Academy of Sciences Leopoldina, and the American Academy of Arts and Sciences. He has received multiple awards for his scientific work, including the Louise-Jeantet Prize in Medicine (2023), the Hans Krebs Award, the Jung Prize, and the Leibniz Prize.